A collaboration between the University of Toronto’s Faculty of Dentistry and the National Jewish Hospital in Denver —the top-ranked respirology research hospital in the U.S. — has yielded a new discovery that could be useful to combat inflammation of all varieties and shows promise in fighting acute respiratory illnesses such as COVID-19.
Called TAT CARMIL1, the discovery is a combination of two naturally occurring peptides that, when combined, work together to penetrate a cell’s membrane in order to dampen an acute inflammatory response.
In this first ex vivo study, the peptide reduced collagen degradation by up to 43 per cent. If deployed early enough, the researchers say, the peptide could allay some of the worst damage caused by acute inflammatory responses.